Prosecution Insights
Last updated: April 19, 2026
Application No. 18/435,375

Sequentially Positioning Sets of Electrode Arrays at Nonoverlapping Positions to Ameliorate Skin Irritation During Tumor Treating Fields (TTFields) Therapy

Non-Final OA §103§112
Filed
Feb 07, 2024
Examiner
LAU, MICHAEL J
Art Unit
3796
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Novocure GmbH
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
3y 0m
To Grant
96%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allow Rate
207 granted / 292 resolved
+0.9% vs TC avg
Strong +25% interview lift
Without
With
+25.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
45 currently pending
Career history
337
Total Applications
across all art units

Statute-Specific Performance

§101
15.2%
-24.8% vs TC avg
§103
51.9%
+11.9% vs TC avg
§102
5.2%
-34.8% vs TC avg
§112
19.0%
-21.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 292 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 4-5 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Regarding claims 4-5, there is insufficient description defining what a ray is supposed to be. For example, is it an arbitrary mathematical ray or is it a physical ray? The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 4-5 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claims 4-5, it is unclear what a ray is supposed to be. For example, is it an arbitrary mathematical ray or is it a physical ray? Further clarification is required. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 1-6, 8-9, 13-16 is/are rejected under 35 U.S.C. 103 as being unpatentable over Kirson (US 11441776 A1). Regarding claims 1 and 13, Kirson discloses A method of applying alternating electric fields to a target region in a subject's body, the body having an anterior surface, a posterior surface, a left surface, and a right surface (eg. multiple embodiments Fig. 1-5, electrode arrays on multiple sides, and respective paragraphs), the method comprising: (a) applying an alternating voltage at a frequency between 50 kHz and 1 MHz (eg. Abstract, Col. 2, Ln. 18- Col. 3, Ln. 67, Col. 4, Ln. 58 – Col. 5, Ln. 51) between a first set of one or more electrode elements positioned on a first region of the anterior surface and a second set of one or more electrode elements positioned on a second region of the posterior surface during a plurality of first portions of a first interval of time (eg. Fig. 4A-B and Col. 10, Ln. 13 – Ln. 22), and applying an alternating voltage at a frequency between 50 kHz and 1 MHz (eg. Abstract, Col. 2, Ln. 18- Col. 3, Ln. 67, Col. 4, Ln. 58 – Col. 5, Ln. 51) between a third set of one or more electrode elements positioned on a third region of the left surface and a fourth set of one or more electrode elements positioned on a fourth region of the right surface (eg. Fig. 4C-D 5A-D, Col. 10, Ln. 22 – Ln. 30) during a plurality of second portions of the first interval of time (eg. Fig. 5A-D, Col. 10, Ln. 66 – Col. 11, Ln. 22); and (b) applying an alternating voltage at a frequency between 50 kHz and 1 MHz between a fifth set of one or more electrode elements positioned on a fifth region of the anterior surface and a sixth set of one or more electrode elements positioned on a sixth region of the posterior surface during a plurality of first portions of a second interval of time (eg. Fig. 5A-D, Col. 10, Ln. 66 – Col. 11, Ln. 56 separate regions such as Fig 5C-D arrays 55/57 and 56-58), and applying an alternating voltage at a frequency between 50 kHz and 1 MHz between a seventh set of one or more electrode elements positioned on a seventh region of the left surface and a eighth set of one or more electrode elements positioned on a eighth region of the right surface during a plurality of second portions of the second interval of time (eg. Fig. 3-5, electrode array 31-32 combined with other side electrodes 51 and 52), wherein the first interval of time and the second interval of time are nonoverlapping (eg. Col. 3, Ln. 25-Col. 4, Ln. 6, Col. 10, Ln. 66- Col. 11, Ln. 22), wherein less than 20% of the fifth region overlaps the first region (eg. Fig. 1 and 3-5, separate regions (eg. Fig. 1 and 3-5, separate regions such as Fig 5C-D arrays 55/57 and 56-58), wherein less than 20% of the sixth region overlaps the second region (eg. Fig. 1 and 3-5, separate regions such as Fig 5C-D arrays 55/57 and 56-58), wherein less than 20% of the seventh region overlaps the third region, and wherein less than 20% of the eighth region overlaps the fourth region (eg. Fig. 3-5, electrode array 31-32 combined with other side electrodes 51 and 52). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have combined the embodiments (Eg. Fig. 1, and 3-5) to have multiple electrodes in various configurations as needed to treat a wide variety of anatomical locations (eg. Col. 11, Ln. 50-56). Regarding claims 2 and 14, Kirson discloses no part of the fifth region overlaps the first region, wherein no part of the sixth region overlaps the second region, wherein no part of the seventh region overlaps the third region, wherein no part of the eighth region overlaps the fourth region (eg. Fig. 1 and 3-5, separate regions (eg. Fig. 1 and 3-5, separate regions such as Fig 5C-D arrays 55/57 and 56-58). Regarding claims 3 and 15 Kirson discloses repeating steps (a) and (b) in an alternating sequence at least ten times. (eg. Col. 3, Ln. 25-Col. 4, Ln. 6, Col. 10, Ln. 66- Col. 11, Ln. 22). Regarding claim 4, Kirson discloses the target region comprises a tumor, the tumor having a centroid, wherein a ray projected directly anterior from the centroid does not intersect the first region, wherein a ray projected directly posterior from the centroid does not intersect the second region, wherein a ray projected directly anterior from the centroid does not intersect the fifth region, and wherein a ray projected directly posterior from the centroid does not intersect the sixth region (Eg. Abstract, Fig. 3-5, Col. 1, Ln. 10-30, Col. 8, Ln. 3 – Col. 11, Ln. 63, it is unclear what the ray is defined since it can mean any geometric ray can come out of a center point and not hit a portion of a region or electrode). Regarding claim 5, Kirson discloses the target region comprises a tumor, the tumor having a centroid, wherein a ray projected directly anterior from the centroid does not intersect at least one of the first region and the fifth region, wherein a ray projected directly posterior from the centroid does not intersect at least one of the second region and the sixth region, wherein a ray projected directly to the left from the centroid does not intersect at least one of the third region and the seventh region, and wherein a ray projected directly to the right from the centroid does not intersect at least one of the fourth region and the eighth region (Eg. Abstract, Fig. 3-5, Col. 1, Ln. 10-30, Col. 8, Ln. 3 – Col. 11, Ln. 63, it is unclear what the ray is defined since it can mean any geometric ray can come out of a center point and not hit a portion of a region or electrode). Regarding claims 6 and 16, Kirson discloses the second interval of time is separated from the first interval of time by less than 48 hours (eg. Col. 9, Ln. 32 – Col. 10, Ln. 12, Col. 10, Ln. 66 – Col. 11, Ln. 22). Regarding claim 8, Kirson discloses each of the alternating voltages has a sinusoidal waveform (eg. Col. 12, Ln. 25-34, Col. 13, Ln. 32 – Col. 14, Ln. 4, AC signals are commonly sinusoidal). Regarding claims 9 Kirson discloses each of the first, second, third, fourth, fifth, sixth,seventh, and eighth regions are located on the subject's abdomen (Eg. Abstract, Fig. 3-5, Col. 1, Ln. 10-30, Col. 8, Ln. 3 – Col. 11, Ln. 63, can have various types of configurations based on anatomy). Claim(s) 7, 10-12, and 17-20 is/are rejected under 35 U.S.C. 103 as being unpatentable over Kirson (US 11441776 A1) in view of Travers (US 2021/0177492 A1). Regarding claims 7 and 17, Kirson discloses the invention of claim 1, but does not disclose the first interval of time is at least 12 hours and the second interval of time is at least 12 hours. Travers teaches a control device for TTF therapy that varies the firing configurations and sequencies by hours and days (eg. Para. 48). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the invention of Kirson to vary the firing configurations and sequences as taught by Travers to optimize treating various tumors in between periods while letting the electrodes cool down (eg. Travers, Para. 48). Regarding claims 10 and 18, the combined invention of Kirson and Travers discloses (c) prior to the first interval of time, positioning the first, second, third, and fourth sets of one or more electrode elements on the first, second, third, and fourth regions, respectively; (d) after the first interval of time, removing the first, second, third, and fourth sets of one or more electrode elements from the subject's body; (e) prior to the second interval of time, positioning the fifth, sixth, seventh, and eighth sets of one or more electrode elements on the fifth, sixth, seventh, and eighth regions, respectively; and (f) after the second interval of time, removing the fifth, sixth, seventh, and eighth sets of one or more electrode elements from the subject's body (Eg. Kirson, Abstract, Fig. 3-5, Col. 1, Ln. 10-30, Col. 8, Ln. 3 – Col. 11, Ln. 63, the switching of the electrode firing configuration and sequencies between different regions is equivalent to taking the non-firing electrodes off since they won’t be firing anyway). Regarding claims 11 and 19, the combined invention of Kirson and Travers discloses repeating steps (a) and (b) in an alternating sequence at least ten times. (eg. Kirson, Col. 3, Ln. 25-Col. 4, Ln. 6, Col. 10, Ln. 66- Col. 11, Ln. 22). Regarding claims 12 and 20, the combined invention of Kirson and Travers discloses each of the primary regions and each of the secondary regions are located on the subject's abdomen (Eg. Kirson, Abstract, Fig. 3-5, Col. 1, Ln. 10-30, Col. 8, Ln. 3 – Col. 11, Ln. 63, can have various types of configurations based on anatomy). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL J LAU whose telephone number is (571)272-2317. The examiner can normally be reached 8-5:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Carl Layno can be reached at 571-272-4949. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL J LAU/Examiner, Art Unit 3796
Read full office action

Prosecution Timeline

Feb 07, 2024
Application Filed
Jan 06, 2026
Non-Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599762
LEAD ANCHOR FOR A NEUROMODULATION LEAD
2y 5m to grant Granted Apr 14, 2026
Patent 12588824
CARDIAC PULSE WAVE RETRIEVAL FROM AN ELECTRICAL SIGNAL
2y 5m to grant Granted Mar 31, 2026
Patent 12588849
GARMENT MEDICAL EXAMINATION SYSTEM
2y 5m to grant Granted Mar 31, 2026
Patent 12582343
METHODS AND SYSTEMS FOR WAVELENGTH MAPPING CARDIAC FIBRILLATION AND OPTIMIZING ABLATION LESION PLACEMENT
2y 5m to grant Granted Mar 24, 2026
Patent 12564443
Tailored Laser Pulses for Surgical Applications
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
96%
With Interview (+25.1%)
3y 0m
Median Time to Grant
Low
PTA Risk
Based on 292 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month